Novel antipsychotics and patient care in state hospitals

Annals of Pharmacotherapy

Volumn 32, Issue 9, 1998, Pages 906-914

  Buckley, Peter F ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antipsychotics; State hospitals

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; WATER;

AGGRESSION; AGRANULOCYTOSIS; AKATHISIA; ALGORITHM; CLINICAL TRIAL; COST CONTROL; DRUG COST; DRUG EFFICACY; DYSPHORIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL; HUMAN; PARKINSONISM; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; WATER INTOXICATION;

AGGRESSION; ANTIPSYCHOTIC AGENTS; HOSPITALS, PSYCHIATRIC; HOSPITALS, STATE; HUMANS; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 0031691842     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17409     Document Type: Review

References (72)

1. Bachrach LL. The state of the state mental hospital in 1996. Psychiatr Serv 1996;47:1071-8.
2. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41.
3. Meyer JM, Simpson GM. From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiatr Serv 1997;48:1137-9.
4. Wilson WH. Clinical review of clozapine treatment in state hospital. Hosp Community Psychiatry 1992;43:700-3.
5. Kane J, Honigfeld G, Singer J, Meltzer HY, the Clozapine Collaborative Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45: 789-96.
6. Essock SM, Hargreaves WA, Dohm F, Goethe J, Carver L, Hipshman L. Clozapine eligibility among state hospital patients. Schizophr Bull 1996; 22:15-25.
7. Chiles J, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint in a state hospital. Hosp Community Psychiatry 1994; 45:269-71.
8. Ebrahim GM, Gibler B, Gacono CB, Hayes G. Patient response to clozapine in a forensic psychiatric hospital. Hosp Community Psychiatry 1994;45:271-3.
9. Manschreck TC, Redmond DA, Beaudette SM. Clozapine in the back wards. Ann Clin Psychiatry 1994;6:215-21.
10. Wilson WH, Claussen AM. 18-month outcome of clozapine treatment for 100 patients in a state hospital. Psychiatr Serv 1995;46:386-9.
11. Wilson WH. Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry 1996;153:951-2.
12. Mishara A, Orr B, Buckley PF. Staff attitudes to clozapine therapy: initial observations. J Psychosoc Nurs 1995;33:44-7.
13. Keck PE, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders. J Clin Psychiatry 1995;56:466-70.
14. Negron AE, Liederman EA, Parkadavil M, Cienfuegos A, Javitt DC. A naturalistic outcome study of risperidone treatment among state hospital patients. Psychiatr Serv 1996;47:1118-20.
15. Buckley PF, Donenwirth K, Bayer KE, Lys C, Ibrahim Z, Schulz SC. Risperidone for treatment-resistant schizophrenia: initial clinical experience in a state hospital. J Pharm Technol 1996;12:271-5.
16. Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching inpatients with treatment resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382-4.
17. Chengappa KNR, Sheth S, Brar JS, Marcus S, Parepally H, Gopalani A, et al. A clinical audit of the first 142 patients who received risperidone at a state psychiatric hospital. Presentation at the Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, May 1997.
18. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
19. Tran PV, Hamilton SH, Kuntz AJ, Potvin H, Andersen SW, Beasley CM, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
20. Arvantis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
21. Rabinowitz J, Avnon M, Rosenberg V. The effect of clozapine on physical and verbal aggression. Schizophr Res 1996;22:249-55.
22. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997;20:427-52.
23. Maier GJ. The impact of clozapine on 25 forensic patients. Bull Am Acad Psychiatry Law 1992;20:247-51.
24. Volavka J, Zito J, Vitrai J, Czobor P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13:287-9.
25. Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-11.
26. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995;15:243-9.
27. Buckley PF, Ibrahim ZY, Singer B, Orr B, Brar PS. Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry Law 1997; 25:173-81.
28. Jeanblanc W, Davis YB. Risperidone for treating dementia-associated aggression (letter). Am J Psychiatry 1995;152:1239.
29. Katz I, Brecher M, Clyde C, Napolitano J, Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia (abstract). Schizophr Res 1998;29:145.
30. Kiesler GM, Beasley CM, Sayler ME, Potvin JH, Sanger TM, Tollefson GD. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia. Presentation at the Winter Workshop on Schizophrenia Research, Davos, Switzerland, February 1998.
31. Hellewell JSE, Cameron-Hands D, Cantillon M. Seroquel: evidence for efficacy in the treatment of hostility and aggression. Schizophr Res 1998;29:154-5.
32. Reinstein M. Concurrent use of clozapine and sodium valproate in the management of aggression in schizophrenia. Presentation at the American Psychiatric Association Annual Meeting, San Diego, CA, May 1997.
33. Sharif ZA, Raza A, Ratakonda S, Kirschner T, Miller CE, Gorman JM. Comparative efficacy of clozapine and risperidone in treatment-refractory schizophrenia (abstract). Schizophr Res 1998;29:147.
34. Buckley PF, Kausch O, Gardner G. Clozapine treatment of schizophrenia: implications for forensic psychiatry. J Clin Forensic Med 1995;2:9-16.
35. Devitt PJ, Masand PS. Risperidone versus conventional neuroleptics in forensic hospital patients. Presentation at the American Psychiatric Association Annual Meeting, New York, May 1996.
36. Verghese C, DeLeon J, Josiassen RC. Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia. Schizophr Bull 1996;22:455-64.
37. Leadbetter RA, Shutty MS. Differential effects of neuroleptics and clozapine on polydipsia and intermittent hyponatremia. J Clin Psychiatry 1994;55(suppl 9B):110-3.
38. Fuller MA, Jurjus G, Kwon K, Konicki PE, Jaskiw GE. Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia. J Clin Psychopharmacol 1996;16:329-32.
39. Kern RS, Marshall BD, Kuehnel TG, Mintz J, Hayden JL, Robertson MJ. Effects of risperidone on polydipsia in chronic schizophrenic patients. J Clin Psychopharmacol 1997;17:432-5.
40. Wilkins JN. Pharmacotherapy of schizophrenia patients with co-morbid substance abuse. Schizophr Bull 1997;23:215-28.
41. Conley RB, Gale E, Hirsch K. Olanzapine response in therapy-refractory schizophrenia with substance abuse (abstract). Schizophr Res 1997;24: 190.
42. Buckley PF, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 1994;151:354-9.
43. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine (letter). Am J Psychiatry 1994;151:959.
44. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatmentresistant mentally ill chemical abuser: a case report and a hypothesis. J Nerv Ment Dis 1994;182:591-2.
45. Safferman AZ, Kane JM, Aronowitz JS, Gordon MF, Pollack S, Lieberman JA. The use of clozapine in neurologic disorders. J Clin Psychiatry 1994;55(suppl B):98-101.
46. Risch C, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-9.
47. Buckley PF. New dimensions in the pharmacologic management of schizophrenia and related psychoses. J Clin Pharmacol 1997;37:363-78.
48. Tamminga CA, Thaker GK, Moran M, Conley RB. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(suppl B):102-6.
49. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-54.
50. Conley RR, Carpenter WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997;154:1243-7.
51. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-20.
52. Adityanjee, Pelonero AL. Prescribing risperidone. Psychiatr Serv 1995; 46:291-2.
53. Klausner M, Bracher M. Risperidone guidelines. Psychiatr Serv 1995; 46:950-1.
54. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-4.
55. Frankenburg FR, Zanarini MC, Cole JO, McElroy SL. Hospitalization rates among clozapine-treated patients. A prospective cost-benefit analysis. Ann Clin Psychiatry 1992;4:247-50.
56. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-8.
57. Reid WH, Mason M, Toprac M. Savings in hospital bed days related to treatment with clozapine. Hosp Community Psychiatry 1994;45:261-4.
58. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-15.
59. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-26.
60. Albright PS, Livingstone S, Keegan DL, Ingham M, Shrikhande S, LeLorier J. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy; a retrospective analysis using the Saskatchewan Health linkable databases. Clin Drug Invest 1996; 11:289-99.
61. Guest JF, Hart WM, Cookson RF, Lindstrom E. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Economics 1996;10:59-67.
62. Thompson D. Costs of treatment with risperidone and clozapine. Report submitted to the San Diego Department of Mental Health. San Diego, CA, 1996.
63. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenia patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997;17:298-307.
64. Viale G, Mechling L, Maislin G, Durkin M, Englehart L. Lawrence BJ. Impact of risperidone on the use of mental health care resources. Psychiatr Serv 1997;48:1153-9.
65. Buckley PF. Novel antipsychotic agents: emerging clinical profiles. J Clin Psychiatry (in press).
66. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Managed Care 1998;4:345-55.
67. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense. Am J Managed Care 1998;4:369-83.
68. Frances A, Docherty JP, Kahn DA, Expert Consensus Group. The Expert Consensus Guideline series. Treatment of schizophrenia. J Clin Psychiatry 1996;57(suppl):1-59.
69. Herz MI, Liberman RP, Lieberman JA, Marder SR, McGlashan TH, Wyatt RJ, et al. American Psychiatric Association practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 (suppl):1-63.
70. Lehman AF, Steinwachs DM, PORT Co-Investigators. Translating research into practice: the schizophrenia PORT treatment recommendations. Schizophr Bull 1998;24:1-10.
71. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry 1997;58(suppl 10):63-72.
72. Srebnik D, Hendryx M, Stevenson J, Caverly S, Dyck DG, Cauce A. Development of outcome indicators for monitoring the quality of public mental health care. Psychiatr Serv 1997;48:903-9.